Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Update

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 10,100 shares, a decrease of 53.5% from the January 31st total of 21,700 shares. Based on an average daily volume of 132,000 shares, the short-interest ratio is presently 0.1 days.

Emmaus Life Sciences Stock Up 6.1 %

Shares of EMMA traded up $0.00 during mid-day trading on Friday, hitting $0.02. 37,484 shares of the company’s stock traded hands, compared to its average volume of 59,380. The business’s 50-day moving average price is $0.02 and its 200-day moving average price is $0.02. Emmaus Life Sciences has a 1 year low of $0.00 and a 1 year high of $0.13. The firm has a market capitalization of $1.12 million, a P/E ratio of -0.19 and a beta of 6.64.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.